{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:05:21Z","timestamp":1790683521984,"version":"4.1.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To present updated information on the role of anti-vascular endothelial growth factor (anti-VEGF) therapy for treating retinopathy of prematurity (ROP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched through PubMed and Scopus databases using the keywords of this article and gathered relevant published articles from the year 2005 to December 2022. The selected articles were classified and summarized, and reasonable conclusions were made accordingly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Considering the current evidence, anti-VEGF agents are superior to laser therapy for the initial treatment of type 1 ROP in zone 1 or posterior zone 2. However, there is a substantial risk of reactivation or persistent avascular retina after solo treatment with anti-VEGFs, and many cases may require laser therapy within the following weeks or months. Thus, vigilant follow-up examinations are mandatory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The role of anti-VEGF agents in the treatment of ROP is indispensable. However, future studies are required to improve indications and dosage and determine long-term ocular and systemic safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/joco.joco_38_23","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T18:32:19Z","timestamp":1717266739000},"page":"125-134","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity"],"prefix":"10.4103","volume":"35","author":[{"given":"M. Hossein","family":"Nowroozzadeh","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Shahriari-Garaee","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Badie","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Banihashemi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Mercer University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunir J.","family":"Garg","sequence":"additional","affiliation":[{"name":"Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"R1-20240910","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R2-20240910","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R3-20240910","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-20240910","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: A report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"R5-20240910","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/IAE.0b013e31820d4000","article-title":"Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity","volume":"31","author":"Axer-Siegel","year":"2011","journal-title":"Retina"},{"key":"R6-20240910","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1055\/s-0040-1710556","article-title":"Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up","volume":"38","author":"Zayek","year":"2021","journal-title":"Am J Perinatol"},{"key":"R7-20240910","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.oret.2017.11.012","article-title":"Analysis of the recurrence of plus disease after intravitreal ranibizumab as a primary monotherapy for severe retinopathy of prematurity","volume":"2","author":"Ar\u00e1mbulo","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R8-20240910","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","article-title":"Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I","volume":"37","author":"Yoon","year":"2017","journal-title":"Retina"},{"key":"R9-20240910","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/IAE.0000000000002943","article-title":"Outcomes of nonconfluent diode laser panretinal photocoagulation for aggressive posterior retinopathy of prematurity after intravitreal bevacizumab","volume":"41","author":"Mammo","year":"2021","journal-title":"Retina"},{"key":"R10-20240910","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","article-title":"Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the RAINBOW trial","volume":"6","author":"Fleck","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"R11-20240910","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: Anatomic outcomes and influencing factors","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"key":"R12-20240910","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: A randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"R13-20240910","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.survophthal.2020.12.002","article-title":"Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes","volume":"66","author":"Popovic","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"R14-20240910","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"key":"R15-20240910","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"R16-20240910","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"R17-20240910","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","article-title":"Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity","volume":"2","author":"Roohipoor","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R18-20240910","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: Timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-20240910","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","article-title":"Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity","volume":"41","author":"Iwahashi","year":"2021","journal-title":"Retina"},{"key":"R20-20240910","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajo.2018.09.039","article-title":"A spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity","volume":"198","author":"Chen","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R21-20240910","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ophtha.2022.05.019","article-title":"Low- and very low-dose bevacizumab for retinopathy of prematurity: Reactivations, additional treatments, and 12-month outcomes","volume":"129","author":"Freedman","year":"2022","journal-title":"Ophthalmology"},{"key":"R22-20240910","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s13063-020-04371-6","article-title":"Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity","volume":"21","author":"Yu","year":"2020","journal-title":"Trials"},{"key":"R23-20240910","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"R24-20240910","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3928\/01913913-20190501-01","article-title":"Persistent avascular retina in infants with a history of type 2 retinopathy of prematurity: To treat or not to treat?","volume":"56","author":"Al-Taie","year":"2019","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R25-20240910","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.oret.2019.01.016","article-title":"Fluorescein angiography in retinopathy of prematurity: Comparison of infants treated with bevacizumab to those with spontaneous regression","volume":"3","author":"Mansukhani","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R26-20240910","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3928\/23258160-20180803-11","article-title":"Late ROP reactivation and retinal detachment in a teenager","volume":"49","author":"Golas","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R27-20240910","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaapos.2021.09.004","article-title":"Prevalence of persistent avascular retina in untreated children with a history of retinopathy of prematurity screening","volume":"26","author":"Hanif","year":"2022","journal-title":"J AAPOS"},{"key":"R28-20240910","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ICU.0000000000000787","article-title":"Adult retinopathy of prematurity: Treatment implications, long term sequelae, and management","volume":"32","author":"Chang","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"R29-20240910","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ophtha.2020.12.028","article-title":"Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal anti-vascular endothelial growth factor","volume":"128","author":"Barry","year":"2021","journal-title":"Ophthalmology"},{"key":"R30-20240910","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: Fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"R31-20240910","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ophtha.2017.09.020","article-title":"Foveal development in infants treated with bevacizumab or laser photocoagulation for retinopathy of prematurity","volume":"125","author":"Vogel","year":"2018","journal-title":"Ophthalmology"},{"key":"R32-20240910","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/bjophthalmol-2019-314610","article-title":"Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation","volume":"104","author":"Chen","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R33-20240910","first-page":"1556","article-title":"Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity","volume":"104","author":"Zhao","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R34-20240910","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/bjophthalmol-2020-317284","article-title":"Comparison of foveal thickness in preschool children with a history of retinopathy of prematurity and laser photocoagulation or anti-vascular endothelial growth factor treatment: A prospective, longitudinal study","volume":"106","author":"Lee","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R35-20240910","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): Prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"R36-20240910","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R37-20240910","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R38-20240910","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R39-20240910","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2022.2887","article-title":"Plasma levels of bevacizumab and vascular endothelial growth factor after low-dose bevacizumab treatment for retinopathy of prematurity in infants","volume":"140","author":"Hartnett","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R40-20240910","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"R41-20240910","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.oret.2020.06.002","article-title":"Acomparison of respiratory outcomes after treating retinopathy of prematurity with laser photocoagulation or intravitreal bevacizumab","volume":"4","author":"Barry","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R42-20240910","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"R43-20240910","doi-asserted-by":"crossref","first-page":"e20183537","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"key":"R44-20240910","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: A prospective case-control study","volume":"126","author":"Fan","year":"2019","journal-title":"Ophthalmology"},{"key":"R45-20240910","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"R46-20240910","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/iovs.62.2.2","article-title":"Brain white matter maturation and early developmental outcomes in preterm infants with retinopathy of prematurity","volume":"62","author":"Ahn","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R47-20240910","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ophtha.2020.11.012","article-title":"Neurodevelopmental outcomes after bevacizumab treatment for retinopathy of prematurity: A meta-analysis","volume":"128","author":"Tsai","year":"2021","journal-title":"Ophthalmology"},{"key":"R48-20240910","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept versus laser photocoagulation on treatment success of retinopathy of prematurity: The FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"R49-20240910","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1097\/IAE.0000000000002754","article-title":"Anatomical and functional results of intravitreal aflibercept monotherapy for type 1 retinopathy of prematurity: One-year outcomes","volume":"40","author":"Chen","year":"2020","journal-title":"Retina"},{"key":"R50-20240910","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"R51-20240910","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R52-20240910","doi-asserted-by":"crossref","first-page":"911095","DOI":"10.3389\/fmed.2022.911095","article-title":"Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1,627 eyes in China","volume":"9","author":"Linghu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R53-20240910","first-page":"1","article-title":"Comparison of clinical effectiveness of conbercept and ranibizumab for treating retinopathy of prematurity: A meta-analysis","volume":"19","author":"Jiang","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"R54-20240910","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000521070","article-title":"The effect of intravitreal bevacizumab dose on retinal vascular progression in retinopathy of prematurity","volume":"245","author":"Bayramoglu","year":"2022","journal-title":"Ophthalmologica"},{"key":"R55-20240910","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"Adosing study of bevacizumab for retinopathy of prematurity: Late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"R56-20240910","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"}],"container-title":["Journal of Current Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_38_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:38:33Z","timestamp":1787773113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_38_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/joco.joco_38_23","relation":{},"ISSN":["2452-2325"],"issn-type":[{"value":"2452-2325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2023-02-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}